Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Partnership Established to Probe the Inner Workings of Colon Cancer

By BiotechDaily International staff writers
Posted on 01 Jul 2013
Image: Eearly stage colon cancer using GE’s cancer mapping technology (Photo courtesy of GE).
Image: Eearly stage colon cancer using GE’s cancer mapping technology (Photo courtesy of GE).
New cancer mapping technology has been designed to provide a more detailed study of cancer cells and may provide better clues into how colon cancer develops, progresses, and how it can be curbed.

Vanderbilt University (Nashville, TN, USA) is collaborating with GE Global Research (Niskayuna, NY, USA), the technology development arm for the General Electric Co. (Fairfield, CT, USA), to better define, at the cellular level, how colon tumors form and develop.

Supported by a five-year, USD 3.75 million grant from the Office of the Director of the National Institutes of Health (NIH; Bethesda, MD, USA), the research will evaluate GE’s innovative cancer mapping technology, an automated platform that can probe and analyze up to 60 different disease markers, including proteins and messenger RNAs, in a single tissue sample. The capability to examine dozens of markers at one time provides a more complete outlook of the actual mechanisms of cancer. Currently, a diagnosis of cancer and the choice of which therapy to prescribe are based on the histology of the tumor, and in some cases, the expression of just one or two disease markers inside a patient’s tumor.

The GE-Vanderbilt project, led by GE scientists Michael Gerdes, PhD and Kashan Shaikh, PhD, and Robert Coffey, MD, a professor of cancer research at Vanderbilt, will examine how intestinal stem cells of the colon contribute to tumor formation and progression, and the signaling pathways associated with the disease.

“With GE’s cancer mapping technology, we’re enabling cancer to be viewed in ways it couldn’t previously be seen such as with the activation of different signaling pathways in specific cells,” said Prof. Gerdes, lead scientist at GE Global Research. “With unprecedented views, we hope will come unprecedented insights that tell us more about how cancer forms, how it progresses, and most importantly, how to defeat it.”

GE scientists have developed cutting-edge technology that allows a single tissue section from a sample that is removed during surgery, to be imaged for biosignatures including expression of dozens of proteins and nucleic acids (RNA and DNA) without destroying the integrity of the sample. “As we have learned, no two patient’s cancer is exactly the same. With colon cancer, some patients exhibit a more aggressive form of the disease compared to other patients,” said John Burczak, advanced technology leader in molecular imaging at GE Global Research. “We want to understand these subtleties, so that one day therapies can even be specifically tailored for each patient.”

Dr. Gerdes added that the goal is to identify “the mechanisms that drive the aggressive nature of the cancer, and the role that cancer stem cells play in therapeutic resistance.”

A major problem in cancer diagnosis is the limited amount of molecular data that is available about a specific cancer. With little information, it is difficult to determine more specific characteristics of cancer that could reveal how fast or gradually it may be growing. New breakthroughs in molecular diagnostics are beginning to change this pattern.

GE’s cancer mapping technology will be tested with investigators at Vanderbilt from the Epithelial Biology Center that Prof. Coffey directs. The Coffey lab recently reported the discovery of a new population of relatively quiescent (inactive) intestinal stem cells. These cells express a protein called Lrig1 that acts as a tumor suppressor. This discovery has “given us an entrée to develop some very robust models of colon cancer,” Prof. Coffey said.

GE Global Research is the hub of technology development for all of GE’s businesses. The company has locations in Niskayuna, NY, USA; San Ramon, CA, USA; Bangalore, India; Shanghai, China; Munich, Germany; and Rio de Janeiro, Brazil.

Related Links:

Vanderbilt University
GE Global Research



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This micrograph depicts the presence of aerobic Gram-negative Neisseria meningitidis diplococcal bacteria; magnification 1150x (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).

Infection by Meningitis Bacteria Depends on Dimerization State of Certain Host Cell Proteins

A team of molecular microbiologists has untangled the complex three-way interaction between the non-integrin laminin receptor (LAMR1), galectin-3 (Gal-2), and the pathogenic bacterium Neisseria meningitidis.... Read more

Drug Discovery

view channel

Molecule in Green Tea Used as Carrier for Anticancer Proteins

A molecule that is a key ingredient in green tea can be employed as a carrier for anticancer proteins, forming a stable and effective therapeutic nanocomplex. This new discovery could help to construct better drug-delivery systems. Some cancer treatments depend on medication comprising the therapeutic drug and a carrier... Read more

Lab Technologies

view channel
Image: The UC Santa Cruz Ebola Genome Portal contains links to the newly created Ebola browser and to scientific literature on the deadly virus (Photo courtesy of UCSC).

Ebola Genome Browser Now Online to Help Scientists’ Respond to Crisis

A US genomics institute has just released a new Ebola genome browser to help international researchers develop a vaccine and antiserum to help stop the spread of the Ebolavirus. The investigators led... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.